Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tests extra ablation targets to stop A-Fib recurrence

NCT ID NCT07197931

Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if burning extra spots outside the main heart veins can better control persistent atrial fibrillation (a type of irregular heartbeat). About 406 adults having their first ablation will be split into two groups: one gets standard vein isolation, the other gets additional trigger ablation. The goal is to see which approach reduces the return of arrhythmia over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 406 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2025

An estimate. Start dates often move.

Expected to finish

Aug 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged ≥19 years with persistent atrial fibrillation scheduled for catheter ablation. * Refractory to or intolerant of at least one Class I or III antiarrhythmic drug. * Undergoing first-time catheter ablation for atrial fibrillation. Exclusion Criteria: * Acute coronary syndrome within the past 3 months. * Severe unrevascularized coronary artery disease: ≥70% stenosis in at least one major epicardial vessel with a diameter ≥2 mm. * History of stroke or transient ischemic attack (TIA) within the past 3 months. * Uncontrolled severe hypertension (systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥120 mmHg). * Severe untreated aortic valve stenosis. * Symptomatic moderate-to-severe valvular heart disease. * Aortic dissection. * Heart failure with reduced ejection fraction (LVEF \<40%). * Severe pulmonary hypertension (resting RVSP \>60 mmHg). * Left atrial anteroposterior diameter \>60 mm. * Presence of cyanotic congenital heart disease. * Obstructive hypertrophic cardiomyopathy (resting or provoked LVOT pressure gradient ≥30 mmHg). * History of prior maze surgery or catheter ablation for atrial fibrillation. * Active internal bleeding. * Contraindications to anticoagulation therapy or rhythm control treatment. * Presence of severe comorbid conditions or life expectancy \<1 year. * Drug or alcohol abuse. * Pregnancy. * Any other condition that, in the investigator's judgment, makes the patient unsuitable for study participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Severance Cardiovascular Hospital, Yonsei University Health System

    Seoul, 120-752, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.